Can You Take Ozempic While Pregnant? What the FDA Label, Animal Studies, and ACOG Actually Say

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• The Ozempic FDA label instructs that semaglutide should be discontinued when pregnancy is recognized; it is not recommended for use in pregnancy.
• Animal reproductive studies in rats, rabbits, and cynomolgus monkeys showed structural abnormalities and embryofetal loss at clinically relevant exposures.
• Novo Nordisk recommends stopping semaglutide at least 2 months before a planned pregnancy because of its long half-life (about 1 week).
• Human pregnancy data come from a small manufacturer registry and a limited number of case series; available evidence cannot confirm or rule out an increased risk of malformations.
• ACOG Committee Opinion 731 on Obesity in Pregnancy (2018, reaffirmed) does not endorse pharmacologic weight loss during pregnancy.

Direct answer

Ozempic is not recommended in pregnancy. The FDA prescribing information directs patients and clinicians to discontinue semaglutide when pregnancy is detected. Animal studies showed fetal harm at high doses, and human data remain limited. If you are pregnant, planning pregnancy, or breastfeeding, do not start, continue, or stop GLP-1 medications without OB-GYN sign-off. The standard of care is to stop semaglutide at least 2 months before conception and use insulin or other approved agents for diabetes care in pregnancy.

Table of contents

1. What the FDA label actually says
2. The animal reproductive toxicity data, in plain English
3. Human exposure data: the registry and case series
4. Why the 2-month washout window exists
5. ACOG and Endocrine Society positions
6. Diabetes care alternatives during pregnancy
7. Obesity in pregnancy: what to do instead
8. If you discover you are pregnant while on Ozempic
9. Decision framework for pre-pregnancy planning
10. The contrary view
11. FAQ
12. Sources

What the FDA label actually says

The Ozempic prescribing information includes specific language under Section 8.1 (Pregnancy). The label states there are limited data with semaglutide use in pregnant women and that based on animal reproduction studies, there may be potential risks to the fetus from exposure during pregnancy. The instruction to clinicians is unambiguous: semaglutide should be discontinued when pregnancy is recognized.

The label also notes that because of the long washout period for semaglutide, the potential risks to a fetus from exposure should be considered when treating women of reproductive potential, and that semaglutide should be discontinued at least 2 months before a planned pregnancy.

This is not a black-box warning. It is a Warnings and Precautions section paired with the Use in Specific Populations subsection. The distinction matters legally and clinically: FDA labeling here reflects animal data plus limited human data, not confirmed human teratogenicity.

The animal reproductive toxicity data, in plain English

Three species were studied during semaglutide development. Each one showed concerning findings, though at exposures that differ from the typical human therapeutic dose.

Species	Findings	Exposure context
Rat	Embryofetal mortality, structural abnormalities, alterations in growth	At maternally toxic doses producing exposures roughly equivalent to or above the maximum recommended human dose (MRHD)
Rabbit	Early pregnancy losses, structural abnormalities	At doses producing exposures less than the MRHD
Cynomolgus monkey	Early pregnancy losses, structural abnormalities (skeletal and visceral)	At exposures comparable to or below the MRHD

The monkey data are the most concerning because exposures sat closer to human therapeutic levels. The rabbit data are also notable because effects appeared at lower exposures than the MRHD. These findings collectively explain why the label uses the word "discontinue" rather than "consider risks and benefits."

Animal data do not directly predict human outcomes. Many drugs have shown animal teratogenicity that did not translate. The point of animal studies is not to declare a drug teratogenic, but to flag a signal that warrants caution while human data accumulate.

Human exposure data: the registry and case series

Novo Nordisk maintains a semaglutide pregnancy exposure registry. Patients exposed during pregnancy or up to 2 months before conception are encouraged to enroll. As of 2024, published analyses remained small and could not establish or rule out a teratogenic effect.

Published case series and pharmacovigilance reports describe inadvertent first-trimester exposures, typically before the patient knew she was pregnant. Most reports have not described a specific pattern of malformations beyond the background rate seen in the general population (roughly 3 to 5 percent of live births). This is reassuring in the limited sense, but the total reported exposures remain too few for meaningful epidemiologic conclusions.

The fundamental problem with human data here: GLP-1 receptor agonists are prescribed predominantly to women trying to lose weight or manage type 2 diabetes, populations that include many women who become pregnant. Yet adherence to discontinuation guidance has been imperfect, and registry enrollment is voluntary. The data we have are not random samples of exposures.

Why the 2-month washout window exists

Semaglutide has a half-life of about 1 week. By the rule of 5 half-lives for near-complete clearance, semaglutide takes roughly 5 weeks to leave the body. The 2-month recommendation builds in additional buffer for individual variability in clearance.

The pharmacokinetic basis matters because patients sometimes interpret "stop when pregnant" as "stop on the positive test." By the time most patients recognize pregnancy (4 to 6 weeks of gestation, often after a missed period), the fetus has already been exposed during organogenesis (weeks 3 to 8). Pre-pregnancy discontinuation is the only way to ensure zero first-trimester exposure.

ACOG and Endocrine Society positions

ACOG has not issued a dedicated guideline on GLP-1 receptor agonists in pregnancy. The most relevant existing document is Committee Opinion 731, Obesity in Pregnancy, originally published in 2018 and reaffirmed. The opinion emphasizes lifestyle counseling, appropriate gestational weight gain, and management of obesity-related comorbidities. It does not endorse pharmacologic weight loss during pregnancy.

The Endocrine Society's 2015 Clinical Practice Guideline on Pharmacological Management of Obesity (with subsequent updates through 2024) recommends against the use of weight-loss medications during pregnancy and breastfeeding. The American Diabetes Association Standards of Care recommend insulin as the preferred pharmacologic agent for diabetes in pregnancy.

Diabetes care alternatives during pregnancy

For pregnant patients with type 2 diabetes, the established alternatives are:

• Insulin. The longest safety record in pregnancy. Multiple regimens (basal-bolus, premixed, pump) accommodate different patient situations.
• Metformin. Crosses the placenta. Has a moderate evidence base in gestational diabetes and pregestational type 2. Used as monotherapy or with insulin in selected patients.
• Glyburide. Used in some gestational diabetes settings, though falling out of favor in many institutions.

The transition from semaglutide to one of these agents should happen before conception when possible, or immediately on pregnancy recognition when it was not. Glycemic targets in pregnancy are tighter than non-pregnant targets, which is its own clinical consideration.

Obesity in pregnancy: what to do instead

For patients who were taking semaglutide for obesity rather than diabetes, the pregnancy approach changes substantially. ACOG recommends:

• Modest gestational weight gain (5 to 9 kg for class I obesity, 5 to 9 kg or less for higher BMI categories, per Institute of Medicine guidance).
• Nutrition counseling and physical activity unless contraindicated.
• Screening and management of obesity-related conditions (sleep apnea, hypertension, gestational diabetes).

Intentional weight loss during pregnancy is not recommended. The goal is appropriate weight gain, not weight loss, even for patients with high baseline BMI.

If you discover you are pregnant while on Ozempic

Inadvertent first-trimester exposure happens. The steps that matter:

1. Stop the medication. Do not take additional doses while awaiting clinician contact.
2. Contact your prescriber. Many prescribers will refer to a maternal-fetal medicine specialist for risk counseling.
3. Schedule an obstetric visit promptly. Confirm pregnancy dating, baseline labs, and prenatal vitamins.
4. Enroll in the manufacturer pregnancy registry. This contributes data that will help future patients.
5. Plan ongoing care. Establish glycemic targets, blood pressure goals, and prenatal screening schedule.

Most patients with inadvertent first-trimester exposure go on to have uneventful pregnancies. The honest framing for counseling is that the absolute risk increase, if any, appears small based on available data, but the data are limited.

Decision framework for pre-pregnancy planning

If you are actively trying to conceive on Ozempic:

• Stop the medication at least 2 months before active attempts at conception.
• Establish a diabetes or obesity care plan that does not include GLP-1 receptor agonists.
• Begin prenatal vitamins with at least 400 mcg of folic acid (higher for some indications).

If you are considering pregnancy in the next year:

• Discuss timing with your prescriber. Some patients benefit from staying on semaglutide longer to optimize health before conception, then transitioning.
• If you have type 2 diabetes, work toward target A1c before conception.
• Address related issues (sleep apnea, hypertension) that may worsen in pregnancy.

If pregnancy is unlikely but possible:

• Use reliable contraception while on semaglutide.
• Be aware that weight loss can restore ovulation in women with PCOS or anovulatory cycles, increasing pregnancy risk.
• Some clinicians recommend pregnancy tests before titrating to higher doses.

The contrary view

Some clinicians argue that the FDA's pregnancy language is more conservative than the evidence requires. Their case rests on three points: animal-to-human translation is imperfect, the human signal so far has not shown a clear pattern of malformation, and severe untreated maternal diabetes or obesity has its own teratogenic and obstetric risks.

This view does not change practice, but it explains why some specialists are willing to counsel patients with inadvertent exposure that the absolute risk is likely modest. It also informs ongoing research, including post-marketing surveillance studies that may eventually produce better risk estimates.

The view that semaglutide is safe in pregnancy is not held by any major specialty society. The cautious framing remains standard.

FAQ

Can you take Ozempic while pregnant? No. Discontinue when pregnancy is recognized and ideally 2 months before conception.

How long before pregnancy should I stop Ozempic? At least 2 months. Semaglutide has a 1-week half-life and takes about 5 weeks for full clearance.

Is Ozempic FDA pregnancy category X? The FDA retired letter categories in 2015. Ozempic falls under the Pregnancy and Lactation Labeling Rule (PLLR) framework. The current label warns against use and instructs discontinuation when pregnancy is recognized.

What did the animal studies show? Reproductive toxicity in rats, rabbits, and cynomolgus monkeys: structural abnormalities, embryofetal mortality, and growth alterations. The monkey data are particularly important because exposures sat near human therapeutic levels.

Is there a human pregnancy registry? Yes. Novo Nordisk maintains one. Published data remain limited.

Does Ozempic cause miscarriage? Animal studies showed embryofetal loss at high doses. Human evidence is limited. Pregnancy loss in the general population is common, which makes causal attribution difficult.

What if I took Ozempic in early pregnancy without knowing? Stop the medication, contact your prescriber and OB-GYN, and consider enrolling in the manufacturer registry. Most reports of inadvertent first-trimester exposure have not described a specific malformation pattern, but the data are limited.

Can I use Ozempic for gestational diabetes? No. Insulin is standard. Metformin and glyburide are used in some settings.

Should I worry about my partner taking Ozempic while we conceive? Animal studies of male fertility have not flagged paternal exposure as a teratogenicity concern. There is no requirement for male partners to discontinue. Discuss any specific concerns with your prescriber.

What should I do if I want to conceive but need weight management? Pre-pregnancy counseling with your primary care, OB-GYN, and possibly an obesity medicine specialist. The window for medication use ends before active conception attempts begin.

Related guides

• Can You Take Ozempic While Breastfeeding? The LactMed Position, Manufacturer Guidance, and What Clinicians Actually Do
• Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation
• Can You Take Zepbound While Pregnant? Tirzepatide-Specific Considerations and Pre-Conception Planning
• Can You Take Mounjaro While Pregnant? The Tirzepatide Diabetes Indication and Pregnancy Pathway
• Getting Pregnant on Ozempic: What to Do in the First 24 Hours and Beyond
• Can You Get Pregnant on Ozempic? Fertility, PCOS, and What Patients Often Underestimate

Sources

1. FDA. Ozempic (semaglutide) injection prescribing information. Novo Nordisk. Most recent label update accessed 2024-2025.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. American College of Obstetricians and Gynecologists. Committee Opinion 731: Obesity in Pregnancy. 2018, reaffirmed.
4. American Diabetes Association. Standards of Care in Diabetes: Management of Diabetes in Pregnancy. Most recent edition.
5. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015 (with subsequent updates).
6. Novo Nordisk. Semaglutide Pregnancy Exposure Registry. Manufacturer-sponsored pharmacovigilance.
7. FDA. Pregnancy and Lactation Labeling Rule (PLLR). Federal Register, 2014.
8. Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. National Academies Press. 2009.
9. Drug Safety Update. Semaglutide and Pregnancy. UK MHRA bulletin, 2023.
10. ClinicalTrials.gov entries for semaglutide post-marketing pregnancy outcomes studies.
11. European Medicines Agency. Ozempic Summary of Product Characteristics. Section 4.6 on fertility, pregnancy, and lactation.
12. ACOG Practice Bulletin 230: Obesity in Pregnancy. 2021.
13. Society for Maternal-Fetal Medicine. Consult Series on Pregnancy Care for Patients with Obesity.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients to independent licensed clinicians and U.S.-based pharmacies. FormBlends does not provide medical care, write prescriptions, or dispense medication. Pregnancy and fertility decisions belong to you and your OB-GYN.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. Pregnancy warnings that apply to FDA-approved semaglutide apply with at least equal weight to compounded formulations, because compounded products have not undergone formal pregnancy safety review.

Results Disclaimer. This article describes risk and benefit considerations in pregnancy. It is not a personalized medical recommendation. Outcomes vary by individual circumstances, gestational age, comorbidities, and clinical judgment.

Trademark Notice. Ozempic is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.